Gennaro Mazzarella1,2, Edoardo Maria Muttillo3,4, Biagio Picardi3, Stefano Rossi3, Irnerio Angelo Muttillo3. 1. Department of General and Emergency Surgery, San Filippo Neri Hospital, Rome, Italy. gennaromazzarella226@gmail.com. 2. Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy. gennaromazzarella226@gmail.com. 3. Department of General and Emergency Surgery, San Filippo Neri Hospital, Rome, Italy. 4. Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Abstract
BACKGROUND: In right-sided colon cancer surgery, currently there is a great deal of discussion and debate regarding complete mesocolic excision (CME) versus conventional right hemicolectomy (CRH) on postoperative outcomes and oncological results. Our aim was to perform a systematic review of the short- and long-term outcomes of CME to standardize surgical approach in patients with right-sided colon cancer. METHODS: A systematic review was performed examining available data on randomized and non-randomized studies evaluating the role of CME and D3 lymphadenectomy in the treatment of right-sided colon cancer, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) standards. RESULTS: After literature search, 919 studies have been recorded, 110 studies underwent full-text reviews and 30 studies met inclusion criteria. The total number of CME procedures was 5931. Postoperative complications was reported in 28 studies with pooled overall complications of 1.88% for CME surgery. Six studies reported 0% of overall postoperative complications and they demonstrated a low incidence of complications following CME procedure. Anastomotic leak was reported in 27 studies with pooled proportion of 0.92% after CME resections. There were 16 papers reporting overall survival following CME procedure, with a mean of 85% of patients survived at 5 years. Mean 5-year overall survival was 93.05% in stage I patients, 89.76% in stage II patients and 79.65% in stage III patients. Local and distant recurrence were included in 21 studies, reporting tumor recurrence rate of 12.25% following CME. 5-year tumor recurrence was 5.8% in stage I patients, 7.68% in stage II patients and 15.69% in stage III patients. CONCLUSIONS: CME does not increase the risk of postoperative complications and significantly improves the long-term oncological impact. Prospective multicentre studies results are needed to verify if CME could be considered standard surgery for right colon cancer.
BACKGROUND: In right-sided colon cancer surgery, currently there is a great deal of discussion and debate regarding complete mesocolic excision (CME) versus conventional right hemicolectomy (CRH) on postoperative outcomes and oncological results. Our aim was to perform a systematic review of the short- and long-term outcomes of CME to standardize surgical approach in patients with right-sided colon cancer. METHODS: A systematic review was performed examining available data on randomized and non-randomized studies evaluating the role of CME and D3 lymphadenectomy in the treatment of right-sided colon cancer, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) standards. RESULTS: After literature search, 919 studies have been recorded, 110 studies underwent full-text reviews and 30 studies met inclusion criteria. The total number of CME procedures was 5931. Postoperative complications was reported in 28 studies with pooled overall complications of 1.88% for CME surgery. Six studies reported 0% of overall postoperative complications and they demonstrated a low incidence of complications following CME procedure. Anastomotic leak was reported in 27 studies with pooled proportion of 0.92% after CME resections. There were 16 papers reporting overall survival following CME procedure, with a mean of 85% of patients survived at 5 years. Mean 5-year overall survival was 93.05% in stage I patients, 89.76% in stage II patients and 79.65% in stage III patients. Local and distant recurrence were included in 21 studies, reporting tumor recurrence rate of 12.25% following CME. 5-year tumor recurrence was 5.8% in stage I patients, 7.68% in stage II patients and 15.69% in stage III patients. CONCLUSIONS: CME does not increase the risk of postoperative complications and significantly improves the long-term oncological impact. Prospective multicentre studies results are needed to verify if CME could be considered standard surgery for right colon cancer.
Authors: Hirotoshi Kobayashi; Nicholas P West; Keiichi Takahashi; Aristoteles Perrakis; Klaus Weber; Werner Hohenberger; Philip Quirke; Kenichi Sugihara Journal: Ann Surg Oncol Date: 2014-02-25 Impact factor: 5.344
Authors: Nicholas P West; Hirotoshi Kobayashi; Keiichi Takahashi; Aristoteles Perrakis; Klaus Weber; Werner Hohenberger; Kenichi Sugihara; Philip Quirke Journal: J Clin Oncol Date: 2012-04-02 Impact factor: 44.544
Authors: C A Bertelsen; A U Neuenschwander; J E Jansen; A Kirkegaard-Klitbo; J R Tenma; M Wilhelmsen; L A Rasmussen; L V Jepsen; B Kristensen; I Gögenur Journal: Br J Surg Date: 2016-01-18 Impact factor: 6.939
Authors: Nicholas P West; Werner Hohenberger; Klaus Weber; Aristoteles Perrakis; Paul J Finan; Philip Quirke Journal: J Clin Oncol Date: 2009-11-30 Impact factor: 44.544
Authors: Claus A Bertelsen; Anders U Neuenschwander; Jens E Jansen; Jutaka R Tenma; Michael Wilhelmsen; Anders Kirkegaard-Klitbo; Else R Iversen; Birgitte Bols; Peter Ingeholm; Leif A Rasmussen; Lars V Jepsen; Pernille W Born; Bent Kristensen; Jakob Kleif Journal: Lancet Oncol Date: 2019-09-13 Impact factor: 41.316
Authors: Giuseppe S Sica; Danilo Vinci; Leandro Siragusa; Bruno Sensi; Andrea M Guida; Vittoria Bellato; Álvaro García-Granero; Gianluca Pellino Journal: Surg Endosc Date: 2022-09-12 Impact factor: 3.453
Authors: Sara Sakjah; Anna Sofie Friis Olsen; Anders Kierkegaard Gundestrup; Pernille Wolder Born; Birgitte Bols; Peter Ingeholm; Jakob Kleif; Claus Anders Bertelsen Journal: Colorectal Dis Date: 2022-04-08 Impact factor: 3.917